322 related articles for article (PubMed ID: 25928741)
21. [A study of general public's trust in government and corporation in the issues of defense and nuclear power policies].
Tsunoda K
Shinrigaku Kenkyu; 2002 Feb; 72(6):535-40. PubMed ID: 11977849
[TBL] [Abstract][Full Text] [Related]
22. Nanotechnology risk perceptions and communication: emerging technologies, emerging challenges.
Pidgeon N; Harthorn B; Satterfield T
Risk Anal; 2011 Nov; 31(11):1694-700. PubMed ID: 22084861
[TBL] [Abstract][Full Text] [Related]
23. Who does the public trust? The case of genetically modified food in the United States.
Lang JT; Hallman WK
Risk Anal; 2005 Oct; 25(5):1241-52. PubMed ID: 16297228
[TBL] [Abstract][Full Text] [Related]
24. Stakeholders' rationales for representing uncertainties of biotechnological research.
Post S; Maier M
Public Underst Sci; 2016 Nov; 25(8):944-960. PubMed ID: 27129955
[TBL] [Abstract][Full Text] [Related]
25. Public awareness and misunderstanding about DrinkWise Australia: a cross-sectional survey of Australian adults.
Brennan E; Wakefield MA; Durkin SJ; Jernigan DH; Dixon HG; Pettigrew S
Aust N Z J Public Health; 2017 Aug; 41(4):352-357. PubMed ID: 28664575
[TBL] [Abstract][Full Text] [Related]
26. Mistrust surrounding vaccination recommendations by the Japanese government: results from a national survey of working-age individuals.
Wada K; Smith DR
BMC Public Health; 2015 Apr; 15():426. PubMed ID: 25928236
[TBL] [Abstract][Full Text] [Related]
27. Environmental attitudes of stakeholders and their perceptions regarding protected area-community conflicts: a case study in China.
Liu J; Ouyang Z; Miao H
J Environ Manage; 2010 Nov; 91(11):2254-62. PubMed ID: 20619528
[TBL] [Abstract][Full Text] [Related]
28. Expert views on regulatory preparedness for managing the risks of nanotechnologies.
Beaudrie CE; Satterfield T; Kandlikar M; Harthorn BH
PLoS One; 2013; 8(11):e80250. PubMed ID: 24244662
[TBL] [Abstract][Full Text] [Related]
29. Public acceptance of nanotechnology foods and food packaging: the influence of affect and trust.
Siegrist M; Cousin ME; Kastenholz H; Wiek A
Appetite; 2007 Sep; 49(2):459-66. PubMed ID: 17442455
[TBL] [Abstract][Full Text] [Related]
30. Government trust, perceptions of COVID-19 and behaviour change: cohort surveys, Singapore.
Lim VW; Lim RL; Tan YR; Soh AS; Tan MX; Othman NB; Borame Dickens S; Thein TL; Lwin MO; Ong RT; Leo YS; Lee VJ; Chen MI
Bull World Health Organ; 2021 Feb; 99(2):92-101. PubMed ID: 33551503
[TBL] [Abstract][Full Text] [Related]
31. The (co-)production of public uncertainty: UK scientific advice on mobile phone health risks.
Stilgoe J
Public Underst Sci; 2007 Jan; 16(1):45-61. PubMed ID: 17575708
[TBL] [Abstract][Full Text] [Related]
32. Labeling of nanotechnology consumer products can influence risk and benefit perceptions.
Siegrist M; Keller C
Risk Anal; 2011 Nov; 31(11):1762-9. PubMed ID: 22084863
[TBL] [Abstract][Full Text] [Related]
33. What determines trust in information about food-related risks? Underlying psychological constructs.
Frewer LJ; Howard C; Hedderley D; Shepherd R
Risk Anal; 1996 Aug; 16(4):473-86. PubMed ID: 8819340
[TBL] [Abstract][Full Text] [Related]
34. Attitudes to genetically modified food over time: How trust in organizations and the media cycle predict support.
Marques MD; Critchley CR; Walshe J
Public Underst Sci; 2015 Jul; 24(5):601-18. PubMed ID: 25063421
[TBL] [Abstract][Full Text] [Related]
35. Enhancing public trust in the food safety regulatory system.
Papadopoulos A; Sargeant JM; Majowicz SE; Sheldrick B; McKeen C; Wilson J; Dewey CE
Health Policy; 2012 Sep; 107(1):98-103. PubMed ID: 22727578
[TBL] [Abstract][Full Text] [Related]
36. Public knowledge and public trust.
Cunningham-Burley S
Community Genet; 2006; 9(3):204-10. PubMed ID: 16741351
[TBL] [Abstract][Full Text] [Related]
37. Deliberating the risks of nanotechnologies for energy and health applications in the United States and United Kingdom.
Pidgeon N; Harthorn BH; Bryant K; Rogers-Hayden T
Nat Nanotechnol; 2009 Feb; 4(2):95-8. PubMed ID: 19197310
[TBL] [Abstract][Full Text] [Related]
38. Trust and transparency in times of crisis: Results from an online survey during the first wave (April 2020) of the COVID-19 epidemic in the UK.
Enria L; Waterlow N; Rogers NT; Brindle H; Lal S; Eggo RM; Lees S; Roberts CH
PLoS One; 2021; 16(2):e0239247. PubMed ID: 33591985
[TBL] [Abstract][Full Text] [Related]
39. Sharing Government Health Data With the Private Sector: Community Attitudes Survey.
Braunack-Mayer A; Fabrianesi B; Street J; O'Shaughnessy P; Carter SM; Engelen L; Carolan L; Bosward R; Roder D; Sproston K
J Med Internet Res; 2021 Oct; 23(10):e24200. PubMed ID: 34596573
[TBL] [Abstract][Full Text] [Related]
40. Understanding the impact of commercialization on public support for scientific research: is it about the funding source or the organization conducting the research.
Critchley CR; Nicol D
Public Underst Sci; 2011 May; 20(3):347-66. PubMed ID: 21796883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
